Conference Calendar

May 20-23 - Current Concepts in Joint Replacement Spring 2012

May 23-25 - 13th EFORT Congress 2012

Complete Calendar »

Earnings Calendar

May 22 @ 8:00 AM ET - Medtronic

Complete Calendar »

Read our research via:
email art

Weekly Email

rss art

RSS



app icon

iPhone

app store icon

Kindle



Orthopedic and Dental Industry News Complete Archive »

Alphatec Spine Appoints New Vice President of Regulatory, Clinical Affairs and Quality BY EDITOR, NOVEMBER 16, 2011

Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, announced today that Frances Harrison, who has over two decades of regulatory, clinical affairs and quality experience in the medical device industry, has been named the Company's Vice President, Regulatory, Clinical Affairs and Quality.

Ms. Harrison will be responsible for providing overall strategic direction and leadership to Alphatec Spine's global regulatory, clinical affairs and quality assurance programs.

Since 2009, Ms. Harrison held the position of Global Vice President, Regulatory Affairs for Covidien in Boulder, CO. She was responsible for global registrations, regulatory compliance and product labeling for a business unit with more than $1 billion in annual sales. Prior to Covidien, Ms. Harrison served as the Global Vice President, Regulatory/Clinical Affairs and Quality Compliance at Lumenis, Ltd., a company that sold surgical, ophthalmic and aesthetic laser systems, as well as class II disposable products. Before working at Lumenis, Ms. Harrison held a series of progressively senior regulatory affairs roles at C.R. Bard, a medical device company that sold products in the vascular, urology, oncology, and surgical specialty markets.

"We are pleased to have Fran Harrison join Alphatec Spine," said Dirk Kuyper, the Company's President and CEO. "Fran's expertise will provide the necessary leadership in a global regulatory environment in which the path to product approval is becoming less predictable, especially as we bring our innovative products to market, both in the U.S. and internationally."

We believe that Fran's experience will provide us with the necessary leadership with respect to regulatory, clinical affairs and quality, which will help us achieve both our short-term and long-term goals."

Email this to a colleague: